{"createdAt":"8/2/2020, 2:38:04 PM","timestamp":1596393484444,"Company ID number":"655","DMX_ISSUER_NAME":"Zhejiang Huahai Pharmaceutical Co., Ltd.","DMX_ISSUER_ID":"IID000000002151652","Country of Classification":"CHINA","name":"Zhejiang Huahai Pharmaceutical Co Ltd ","code":"600521","stock_exchange":"Shanghai Stock Exchange","people":[{"id":"浙江华海药业股份有限公司_李宏","group":"board","name":"李宏","title":"董事长,董事","isMale":true,"age":"59","degree":"本科","salary":"80.00万","stockAmount":"-","description":"李宏先生:59岁,工学学士学位。2008年9月至2015年1月任工业和信息化部消费品工业司医药处处长;2015年1月至2017年7月,任工业和信息化部产业促进中心副主任;2017年8月至2017年12月,任工业和信息化部产业促进中心名誉顾问;2018年1月至2018年9月;任中国生物技术股份有限公司战略发展顾问兼工业和信息化部产业促进中心名誉顾问;2018年10月至今担任工业和信息化部产业促进中心名誉顾问。","lastUpdated":"2019-05-23"},{"id":"浙江华海药业股份有限公司_杜军","group":"board","name":"杜军","title":"副董事长,董事","isMale":true,"age":"64","degree":"硕士","salary":"404.3万","stockAmount":"168万","description":"杜军先生:64岁,硕士。曾任美国新泽西州多项技术测试公司化学师兼质量管理经理;美国环境管理公司下属化学污染管理公司美东区中心测试研究所有机所所长;美国美都股份有限公司副总经理兼工程设计部经理。现任浙江美阳国际工程设计有限公司董事长、浙江华海药业股份有限公司副董事长、华海(美国)国际有限公司总经理。","lastUpdated":"2019-05-23"},{"id":"浙江华海药业股份有限公司_陈保华","group":"board","name":"陈保华","title":"董事","isMale":true,"age":"58","degree":"本科","salary":"180.0万","stockAmount":"3.657亿","description":"陈保华,男,本科学历,高级工程师。1989年1月开始创建临海市汛桥合成化工厂,并先后担任临海市华海合成化工厂厂长,浙江华海医药化工有限公司,浙江华海药业有限公司,浙江华海药业集团有限公司总经理。现任华海药业董事兼总经理。","lastUpdated":"2019-05-23"},{"id":"浙江华海药业股份有限公司_祝永华","group":"board","name":"祝永华","title":"董事","isMale":true,"age":"55","degree":"大专","salary":"175.0万","stockAmount":"138.1万","description":"祝永华先生:大专学历,经济师。曾任中国工商银行临海市支行信贷科副科长,浙江临亚集团有限公司副总经理,上海嘉圣染丝有限公司副总经理。现任浙江华海药业股份有限公司副总经理兼董事会秘书。","lastUpdated":"2019-05-23"},{"id":"浙江华海药业股份有限公司_单伟光","group":"board","name":"单伟光","title":"董事","isMale":true,"age":"59","degree":"","salary":"--","stockAmount":"1.236万","description":"单伟光先生,1961年6月出生,中国国籍,无境外居留权,浙江工业大学教授、博士生导师、《药物分析杂志》编委。曾任浙江工业大学化工学院党总支副书记;浙江工业大学科技处副处长;浙江工业大学研究生处常务副主任;现任浙江工业大学药学院院长、浙江华海药业股份有限公司董事、浙江珍诚医药在线股份有限公司独立董事。","lastUpdated":"2019-05-22"},{"id":"浙江华海药业股份有限公司_苏严","group":"board","name":"苏严","title":"董事","isMale":true,"age":"48","degree":"硕士","salary":"--","stockAmount":"89.35万","description":"苏严,男,1972年2月出生,工商管理硕士,汉族。曾任清华紫光科技创新投资有限公司总经理助理,浙江华海药业股份有限公司董事兼投资部经理,北京亚都室内环保科技股份有限公司总裁助理,北京拂尘龙科技发展有限公司财务负责人,北京东方广视科技股份有限公司副总经理兼董事会秘书,汉喜普泰(北京)医院投资管理有限公司总经理,辽宁时代万恒股份有限公司独立董事。现任崇德弘信(北京)投资管理有限公司总经理,三友化工独立董事，浙江华海药业股份有限公司董事。2008年取得上海证券交易所上市公司独立董事资格培训证书。","lastUpdated":"2019-05-22"},{"id":"浙江华海药业股份有限公司_王玉民","group":"board","name":"王玉民","title":"独立董事","isMale":true,"age":"65","degree":"本科","salary":"12.00万","stockAmount":"-","description":"王玉民先生:65岁,本科学历,研究员。曾任第四军医大学讲师,总后勤部卫生部助理员,军事医学科学院科技部处长、部长、研究员、博士生导师,总后勤部卫生部副部长,中国预防性艾滋病基金会理事长。现任浙江华海药业股份有限公司独立董事、中国生殖健康产业协会副理事长。","lastUpdated":"2019-05-22"},{"id":"浙江华海药业股份有限公司_辛金国","group":"board","name":"辛金国","title":"独立董事","isMale":true,"age":"58","degree":"博士","salary":"6.000万","stockAmount":"-","description":"辛金国先生:中国国籍,1962年生,博士学位,研究生学历,中国注册会计师非执业会员。现任浙江杭州电子科技大学会计学教授、博士生导师,杭州电子科技大学浙江省信息化与经济社会发展研究中心常务副主任、浙江华海药业股份有限公司独立董事、杭州鸿泉物联网技术股份有限公司独立董事、浙江永宁药业股份有限公司独立董事,传化智联股份有限公司独立董事。","lastUpdated":"2019-05-22"},{"id":"浙江华海药业股份有限公司_曾苏","group":"board","name":"曾苏","title":"独立董事","isMale":true,"age":"61","degree":"博士","salary":"12.00万","stockAmount":"-","description":"曾苏先生,1959年出生,中国国籍,无境外居留权,研究生学历,博士,教授。曾任浙江长广煤矿公司医院药师、浙江医科大学讲师、美国犹他大学访问学者、浙江医科大学教授、美国南卡医科大学高级访问学者。现为浙江大学教授,浙江康恩贝制药股份有限公司独立董事、杭州泰格医药科技股份有限公司独立董事、杭州先导医药科技有限责任公司董事长、浙江华海药业股份有限公司独立董事。","lastUpdated":"2019-05-22"},{"id":"浙江华海药业股份有限公司_王虎根","group":"supervisoryCommittee","name":"王虎根","title":"监事会召集人","isMale":true,"age":"70","degree":"硕士","salary":"--","stockAmount":"-","description":"王虎根先生:1950年3月生,中国籍、未有境外居留权,研究生学历。历任浙江省卫生厅药政局副局长兼浙江省GMP认证办公室主任,浙江省医学科学院副院长兼浙江省医学科学院药物发开中心主任、副研究员、研究员,浙江莎普爱思药业股份有限公司独立董事,万邦德制药集团股份有限公司监事会主席。现任浙江迦南科技股份有限公司独立董事,华北制药股份有限公司独立董事,浙江华海药业股份有限公司监事会主席,万邦德医药控股集团股份有限公司监事会主席。","lastUpdated":"2019-05-23"},{"id":"浙江华海药业股份有限公司_唐秀智","group":"supervisoryCommittee","name":"唐秀智","title":"监事","isMale":false,"age":"59","degree":"大专","salary":"--","stockAmount":"-","description":"唐秀智,女,1961年4月出生,大专学历,高级会计师.曾任浙江海宏集团会计,浙江海宏集团财务部经理,浙江海宏集团副总经理,财务部经理。2010年至今担任浙江海宏液压科技股份有限公司总经理、党委书记。","lastUpdated":"2019-05-22"},{"id":"浙江华海药业股份有限公司_孟艳华","group":"supervisoryCommittee","name":"孟艳华","title":"职工监事","isMale":false,"age":"41","degree":"本科","salary":"126.6万","stockAmount":"-","description":"孟艳华:女,41岁,中国国籍,武汉化工学院工业分析专业,学士学位,毕业后至今就职于浙江华海药业股份有限公司。2002年7月至2004年8月,就职于公司质量管理部门,任质量管理员;2004年9月至2011年7月就职于公司总裁办公室,任主任助理职务;2011年8月至2016年2月就职于公司汛桥分厂,任厂长职务;2016年3月至2017年11月,任公司总裁助理兼公司总裁办公室主任职务;2017年12月至今任浙江华海药业股份有限公司总裁助理兼原料药事业部总经理职务。","lastUpdated":"2019-04-30"},{"id":"浙江华海药业股份有限公司_陈保华","group":"manager","name":"陈保华","title":"总经理","isMale":true,"age":"58","degree":"本科","salary":"180.0万","stockAmount":"3.657亿","description":"陈保华,男,本科学历,高级工程师。1989年1月开始创建临海市汛桥合成化工厂,并先后担任临海市华海合成化工厂厂长,浙江华海医药化工有限公司,浙江华海药业有限公司,浙江华海药业集团有限公司总经理。现任华海药业董事兼总经理。","lastUpdated":"2019-05-23"},{"id":"浙江华海药业股份有限公司_祝永华","group":"manager","name":"祝永华","title":"董事会秘书,副总裁","isMale":true,"age":"55","degree":"大专","salary":"175.0万","stockAmount":"138.1万","description":"祝永华先生:大专学历,经济师。曾任中国工商银行临海市支行信贷科副科长,浙江临亚集团有限公司副总经理,上海嘉圣染丝有限公司副总经理。现任浙江华海药业股份有限公司副总经理兼董事会秘书。","lastUpdated":"2019-05-23"},{"id":"浙江华海药业股份有限公司_陈其茂","group":"manager","name":"陈其茂","title":"副总裁","isMale":true,"age":"62","degree":"中专","salary":"165.0万","stockAmount":"88.28万","description":"陈其茂先生:中专学历。2004年至今任浙江华海药业股份有限公司副总经理。","lastUpdated":"2019-05-23"},{"id":"浙江华海药业股份有限公司_王杰","group":"manager","name":"王杰","title":"副总裁","isMale":true,"age":"55","degree":"本科","salary":"211.0万","stockAmount":"7.465万","description":"王杰先生:55岁,大连外国语大学英语语言文学学士。2010年4月至2012年1月任上海迪赛诺药业有限公司副总经理、总经理;2013年3月至今任浙江华海药业股份有限公司副总裁。","lastUpdated":"2019-05-23"},{"id":"浙江华海药业股份有限公司_张红","group":"manager","name":"张红","title":"副总裁","isMale":false,"age":"53","degree":"大专","salary":"130.0万","stockAmount":"4.118万","description":"张红女士:53岁,北京信息工程学院管理信息工程专业,大专。2007年7月-2012年12月,任职于华润双鹤药业股份有限公司公共事务政府事务负责人并兼任中国医药企业管理协会常务副秘书长。2013年3月至今任浙江华海药业股份有限公司副总裁兼北京办事处主任。","lastUpdated":"2019-05-23"},{"id":"浙江华海药业股份有限公司_徐波","group":"manager","name":"徐波","title":"副总裁","isMale":true,"age":"46","degree":"硕士","salary":"132.0万","stockAmount":"-","description":"徐波:男,副研究员,天津医科大学本科,南开大学EMBA。2005年至2009年任天津药物研究院科研开发处副处长;2009年至2010年任天津药物研究院投资处处长;2010年至2013年5月任先声药业集团注册总监兼研究院副院长。现任浙江华海药业股份有限公司副总经理。","lastUpdated":"2019-05-23"},{"id":"浙江华海药业股份有限公司_郭斯嘉","group":"manager","name":"郭斯嘉","title":"副总裁","isMale":true,"age":"57","degree":"硕士","salary":"165.0万","stockAmount":"-","description":"郭斯嘉:男,1963年12月出生,中国国籍,中央党校经济学专业研究生,高级项目管理师。2004年3月至2017年3月,曾任台州港务集团有限公司党委书记、董事长;任台州市水库移民管理办公室主任、市水利局副局长、党组成员(兼)等职务。现任浙江华海药业股份有限公司董事兼副总裁。","lastUpdated":"2019-05-23"},{"id":"浙江华海药业股份有限公司_陈敦渊","group":"manager","name":"陈敦渊","title":"副总裁","isMale":true,"age":"53","degree":"","salary":"162.0万","stockAmount":"-","description":"陈敦渊先生:53岁,1988年至2013年就职于临海市环保局;2013年就职于临海头门港新区管理委员会,担任党委委员、医化园区副主任职务;2017年10月至今任浙江华海药业股份有限公司副总裁。","lastUpdated":"2019-05-23"},{"id":"浙江华海药业股份有限公司_尚飞","group":"manager","name":"尚飞","title":"副总裁","isMale":false,"age":"51","degree":"硕士","salary":"121.4万","stockAmount":"-","description":"尚飞女士:1969年6月出生,硕士,医药高级工程师,注册执业药师。曾就职于大连辉瑞制药有限公司,杭州赛诺菲制药有限公司,北京诺华制药有限公司,玛氏中国有限公司,中美史克制药有限公司,历任QC分析员,QC经理,质量总监,研发负责人,供应链质量及商业运营负责人。2017年1月至2019年1月就职于联化科技股份有限公司,任医药事业部质量与合规负责人。2019年1月至今任浙江华海药业股份有限公司质量副总裁。","lastUpdated":"2019-05-23"},{"id":"浙江华海药业股份有限公司_李敏","group":"manager","name":"李敏","title":"副总裁","isMale":true,"age":"58","degree":"博士","salary":"236.7万","stockAmount":"-","description":"李敏,男,美国国籍,1962年出生,美国约翰霍普金斯大学化学博士学历。曾任美国先灵葆雅Schering-Plough经理;美国默克公司上市药品分析化学科学部副总监。","lastUpdated":"2019-05-23"},{"id":"浙江华海药业股份有限公司_王祎华","group":"manager","name":"王祎华","title":"副总裁","isMale":false,"age":"52","degree":"本科","salary":"136.0万","stockAmount":"4461","description":"王祎华,女,中国国籍,无境外永久居留权,1968年出生,对外经济贸易大学经济学学士学位,国际商务师。1990年8月至2014年5月任职于中化江苏有限公司副总经理。现任浙江华海药业股份有限公司下属子公司江苏云舒海进出口有限公司总经理。","lastUpdated":"2019-05-23"},{"id":"浙江华海药业股份有限公司_张美","group":"manager","name":"张美","title":"财务负责人","isMale":false,"age":"45","degree":"本科","salary":"110.5万","stockAmount":"61.48万","description":"张美女士:会计师。2008年6月至今任浙江华海药业股份有限公司财务负责人。","lastUpdated":"2019-05-23"}],"companyName":"浙江华海药业股份有限公司","province":"浙江省","englishName":"Zhejiang Huahai Pharmaceutical Co., Ltd.","industry":"医药生物 — 化学制药","website":"www.huahaipharm.com","mainBusiness":"原料药及医药中间体的制造和销售。","productsName":["甲磺酸帕罗西汀胶囊","盐酸强力霉素缓释片","氯沙坦钾片","盐酸帕罗西汀片","盐酸多奈哌齐片","拉莫三嗪缓释片","安非他酮缓释片","普利类","沙坦类药物"],"actualController":"陈保华","actualControllerSharePercentage":"25.14%","registeredCapital":"14.55亿元","employeeAmount":"6050","phone":"86-0576-85991096","location":"浙江省台州市临海市汛桥","chineseDescription":"浙江华海药业股份有限公司是一家主要经营原料药、医药中间体、制剂的生产和销售的公司。公司的主要产品有普利类、沙坦类等高血压原料药。\n　　公司是国内首家通过美国FDA制剂认证的企业，在国际GMP认证、制剂以及原料药的海外注册、国际合作等领域处于国内同行业领先地位。","foundedDate":"1998-12-29","goPublicDate":"2003-03-04","companyHistory":"浙江华海药业股份有限公司（以下简称公司或本公司）系经浙江省人民政府企业上市工作领导小组浙上市〔2001〕5号文批准，由陈保华、周明华、清华紫光科技创新投资有限公司、北京东方经典商务顾问有限公司、浙江美阳国际石化医药工程设计有限公司、宁波泰达进出口有限公司、时惠麟共同发起设立，于2001年2月28日在浙江省工商行政管理局登记注册，总部位于浙江省临海市。公司现持有统一社会信用代码为91330000147968817N的营业执照，注册资本1,031,079,103.00元，股份总数1,031,079,103股（每股面值1元）。其中，有限售条件的流通股份9,425,650股；无限售条件的流通股份1,021,653,453股。公司股票已于2003年3月4日在上海证券交易所挂牌交易。收起▲","shareholders":[{"organizationId":"","holderName":"陈保华","totalShare":"3.32亿","sharePercentage":"25.14%"},{"organizationId":"","holderName":"周明华","totalShare":"2.41亿","sharePercentage":"18.21%"},{"organizationId":"T000247073","holderName":"台州市金融投资集团有限公司","totalShare":"2556.28万","sharePercentage":"1.93%"},{"organizationId":"T000280241","holderName":"中央汇金资产管理有限责任公司","totalShare":"1836.63万","sharePercentage":"1.39%"},{"organizationId":"Q00410D111","holderName":"国开装备产业投资基金(天津)合伙企业(有限合伙)","totalShare":"1815.54万","sharePercentage":"1.37%"},{"organizationId":"T000125370","holderName":"香港中央结算有限公司","totalShare":"1764.72万","sharePercentage":"1.33%"},{"organizationId":"","holderName":"泰康人寿保险有限责任公司-投连-创新动力","totalShare":"1716.25万","sharePercentage":"1.30%"},{"organizationId":"","holderName":"翁震宇","totalShare":"1701.42万","sharePercentage":"1.29%"},{"organizationId":"T004616735","holderName":"兴业国信资产管理有限公司-台州稳晟股权投资合伙企业(有限合伙)","totalShare":"1452.43万","sharePercentage":"1.10%"},{"organizationId":"","holderName":"浙江华海药业股份有限公司-2015年员工持股计划","totalShare":"1436.47万","sharePercentage":"1.09%"}],"englishDescription":"ZHEJIANGHUAHAIPHARMACEUTICALCO., LTD is a China-based company, principally engaged in the manufacture and distribution of active pharmaceutical ingredients (APIs), intermediates and preparations. The Company's main products are classified as -pril series, -sartan series and preparations, including irbesartan tablets, paroxetine hydrochloride tablets, risperidone tablets, fosinopril sodium tablets, as well as irbesartan and hydrochlorothinzide tablets, among others. The Company also provides related technical support services. The Company distributes its products in domestic and overseas markets.","englishIndustry":"Biotechnology & Drugs","Price to earnings (ttm)":"83.05","Price to sales (ttm)":"9.72","Price to book (mrq)":"9.60","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"53.50","Lt debt to equity (mrq)":"24.41","Return on investment (ttm)":"10.33","Return on equity (ttm)":"6.50","Income statement":{},"Balance sheet":{},"Cash flow":{"Cash receipts":"5,620.60","Cash payments":"(1,567.93)","Cash taxes paid":"(183.22)","Changes in working capital":"(2,115.50)","Cash from operating activities":"1,753.95","Capital expenditures":"(794.31)","Other investing cash flow items, total":"3.25","Cash from investing activities":"(791.06)","Financing cash flow items":"59.37","Total cash dividends paid":"(208.88)","Issuance (retirement) of debt, net":"(250.82)","Cash from financing activities":"(400.33)","Foreign exchange effects":"28.69","Net change in cash":"591.25"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"38.50","52 Week High":"39.82","52 Week Low":"12.80","Pricing date":"","10 Day Average Trading Volume":"24.74","Market Capitalization":"56,002.41","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"471.17","Beta":"0.83","1 Day Price Change":"-1.16","13 Week Price Return (Daily)":"63.51","26 Week Price Return (Daily)":"142.14","5 Day Price Return (Daily)":"3.30","52 Week Price Return (Daily)":"163.86","Year To Date Price Return (Daily)":"145.36","Month to Date Price Return (Daily)":"13.47","Price Relative to S&P500 (4 Week)":"10.36","Price Relative to S&P500 (13 Week)":"41.29","Price Relative to S&P500 (26 Week)":"117.74","Price Relative to S&P500 (52 Week)":"131.88","Price Relative to S&P500 (YTD)":"126.10"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"0.41","EPS excl. Extra Items (TTM)":"0.46","EPS Normalized (Annual)":"0.46","Revenue per Share (Annual)":"3.87","Revenue per Share (TTM)":"4.06","Book Value (Per Share Annual)":"3.86","Book Value (Per Share Quarterly)":"4.01","Tangible Book Value (Per Share Annual)":"3.16","Tangible Book Value (Per Share Quarterly)":"3.30","Cash Per Share (Per Share Annual)":"1.04","Cash Per Share (Per Share Quarterly)":"0.87","Cash Flow (Per Share Annual)":"0.73","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.18","Dividends (Per Share TTM)":"0.18","EBITD (Per Share TTM)":"0.85","EPS Basic excl. Extra Items (Annual)":"0.41","EPS Basic excl. Extra Items (TTM)":"0.46","EPS incl. Extra Items (Annual)":"0.41","EPS incl. Extra Items (TTM)":"0.46","Free Cash Flow (Per Share TTM)":"0.60","Dividend (Per Share 5Y)":"0.12"},"Valuation":{"P/E excl. Extra Items (Annual)":"94.11","P/E excl. Extra Items (TTM)":"83.05","P/E Normalized (Annual)":"83.23","Price to sales (Annual)":"10.39","Price to sales (TTM)":"9.72","Price to Tangible Book (Annual)":"12.20","Price to Tangible Book (Quarterly)":"11.66","Price to Free Cash Flow (Per Share Annual)":"74.59","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"65.61","Price to Book (Annual)":"9.98","Price to Book (Quarterly)":"9.60","P/E Basic excl. Extra Items (TTM)":"50.40","P/E excl. Extra Items High (TTM)":"238.67","P/E excl. Extra Items Low (TTM)":"38.23","P/E incl. Extra Items (TTM)":"83.05","Net Debt (Interim)":"1,856.42","Net Debt (Annual)":"2,001.59","Dividend Yield (5Y)":"0.73","Dividend Yield":"0.47","Current Dividend Yield (TTM)":"0.47"},"Financial Strength":{"Free Cash Flow (Annual)":"750.76","Current Ratio (Annual)":"1.57","Net Interest coverage (Annual)":"5.85","Long Term Debt/Equity (Annual)":"21.02","Payout Ratio (Annual)":"46.43","Quick Ratio (Annual)":"0.91","Total Debt/Total Equity (Annual)":"62.54","Current EV/Free Cash Flow (Annual)":"3,241.82","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"1.85","Long Term Debt/Equity (Quarterly)":"24.41","Quick Ratio (Quarterly)":"1.09","Total Debt/Total Equity (Quarterly)":"53.50","Free Cash Flow (TTM)":"853.51","Net Interest Coverage (TTM)":"8.09","Payout Ratio (TTM)":"40.40"},"Margins":{"Gross Margin (Annual)":"60.54","Gross Margin (TTM)":"60.11","Net Profit Margin % (Annual)":"11.26","Net Profit Margin (TTM)":"12.13","Operating Margin (Annual)":"15.30","Operating Margin (TTM)":"16.50","Pretax Margin (TTM)":"15.36","Pretax Margin (Annual)":"14.12","Operating Margin (5Y)":"13.40","Pretax Margin (5Y)":"12.08","Free Operating Cash Flow/Revenue (5Y)":"-8.51","Free Operating Cash Flow/Revenue (TTM)":"14.82","Gross Margin (5Y)":"55.76","Net Profit Margin (5Y)":"9.79"},"Management Effectiveness":{"Return on Assets (Annual)":"5.75","Return on Equity (TTM)":"6.50","Return on Average Equity (Annual)":"11.77","Return on Average equity (TTM)":"13.05","Return on Investment (Annual)":"9.58","Return on Investment (TTM)":"10.33","Return on Average Assets (5Y)":"5.87","Return on Average Equity (5Y)":"10.59","Return on Investment (5Y)":"9.15","Asset Turnover (Annual)":"0.51","Asset Turnover (TTM)":"0.54","Inventory Turnover (Annual)":"0.97","Inventory Turnover (TTM)":"1.11","Net Income/Employee (Annual)":"98,960.38","Net Income/Employee (TTM)":"115,523.70","Receivables Turnover (Annual)":"3.39","Receivables Turnover (TTM)":"3.50","Revenue/Employee (Annual)":"878,684.70","Revenue/Employee (TTM)":"951,995.00"},"Growth":{"Revenue Growth (Quarterly YoY)":"30.98","Revenue Growth Rate (5Y)":"15.82","EPS Growth (Quarterly YoY)":"53.93","EPS Growth (TTM YoY)":"685.16","EPS Growth Rate (5Y)":"15.74","Dividend Growth Rate (3Y)":"10.07","Revenue Growth (TTM YoY)":"13.95","Revenue Growth (Per Share 5Y)":"15.08","Revenue Growth Rate (3Y)":"9.60","EPS Growth Rate (3Y)":"3.35","Book Value Growth Rate (Per Share 5Y)":"10.05","Tangible Book Value Total Equity CAGR (5Y)":"10.09","Capital Spending growth rate 5 year":"12.69","EBITDA CAGR (5Y)":"25.81","EBITDA Interim CAGR (5Y)":"24.68","Free Operating Cash Flow CAGR (5Y)":"--","Total Debt CAGR (5Y)":"35.41","Net Profit Margin Growth Rate (5Y)":"2.55"},"Income Statement":{"Revenue (Annual)":"5,388.10","Revenue (TTM)":"5,759.57","EBITD (Annual)":"1,513.17","EBITD (TTM)":"1,202.46","Earnings Before Taxes (Annual)":"760.86","Earnings Before Taxes (TTM)":"884.40","Net Income to Common (Annual)":"569.60","Net Income to Common (TTM)":"654.66","Earnings Before Taxes Normalized (Annual)":"854.26","Net Income Available to Common Normalized (Annual)":"644.08","Diluted Normalized EPS excl. Extra Items (TTM)":"0.51"}}}